Full-Time

Senior Principal Source to Pay Technology

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$177.6k - $266.4k/yr

+ Annual bonus + Annual equity awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid work allows remote work up to two days per week, or five days per week on-site.

Bachelor's

Category
AI & Machine Learning (1)
Required Skills
Agile
Machine Learning
Coupa
DevOps

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • Experience with Source to Pay technologies, including Icertis, ProcessUnity, DocuSign, Coupa, and Source to Pay Orchestration tools.
  • In-depth knowledge and hands-on experience implementing artificial intelligence and machine learning technologies.
  • Ability to translate business challenges into artificial-intelligence-driven solutions with measurable outcomes.
  • Functional and technical expertise with application configurations, integrations, and documentation.
  • Ability to understand, analyze, and document complex business processes and translate business needs and functional requirements into technical or process-driven solutions.
  • Experience in program management, project management, demand management, resource management, and system lifecycle management.
  • Proven track record of on-time project delivery for large, complex projects with global stakeholders.
  • In-depth experience designing, developing, and deploying technology solutions using agile software development practices and a DevOps model.
  • Ability to solve complex business problems by collaborating across organizational boundaries.
  • Bachelor's degree in a technology discipline or equivalent.
  • At least 8 years of work experience with relevant business systems in the Life Sciences industry, or an equivalent combination of education and experience.
Responsibilities
  • Provide technical expertise, delivery, and support for Source to Pay artificial-intelligence-powered technologies.
  • Implement and maintain Source to Pay Orchestration solutions and artificial intelligence capabilities.
  • Partner with business leadership to identify and prioritize opportunities to improve business processes with innovative technology and data.
  • Gather and refine requirements, determine solution-design options, deliver enhancements, support integrations, and contribute to technology projects and initiatives.
  • Advise business stakeholders on Source to Pay technology and artificial-intelligence solutions.
  • Collaborate with business stakeholders to understand current and future-state strategy, needs, and requirements from a global perspective.
  • Implement artificial-intelligence capabilities in the Source to Pay space while meeting compliance, legal, ethical, data-privacy, and regulatory requirements.
  • Offer innovative technologies, solution ideas, and business-process improvements to drive efficiencies and meet business needs.
  • Facilitate workshops and discussions to collect and document user stories and requirements.
  • Develop and document functional and technical aspects of integrations with upstream and downstream platforms.
  • Design, perform, and document system configurations within in-scope platforms and applications.
  • Contribute to creating and documenting testing strategies and execution plans.
  • Work with offshore team members and peers on platform support and technical development of enhancements and projects.
  • Manage relationships with strategic software vendors and managed service providers as needed.
  • Work with Privacy, DTE Compliance, and Internal Audit to ensure compliance with regulations, data-integrity policies, and Vertex's system lifecycle and change-management processes.
Desired Qualifications
  • Preferred experience with ZipHQ.
  • Experience working with implementation partners, managed services providers, and offshore teams.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex raised 2026 revenue guidance to $13.1-$13.2 billion after Q2 growth.
  • Povetacicept has a November 30, 2026 PDUFA date, opening nephrology revenue.
  • JOURNAVX hit $50 million in Q2 2026, while CASGEVY grew 151% year over year.

What critics are saying

  • Sionna axed SION-719 on August 10, 2026, but CF competition keeps advancing.
  • Zimislecel faced a voluntary manufacturing pause in 2026, exposing cell-therapy execution risk.
  • Crinetics adds $8.8 billion integration risk; a failed close leaves Vertex overdependent on CF.

What makes Vertex Pharmaceuticals unique

  • Vertex still owns CFTR modulators; Q2 2026 CF revenue reached $3.2 billion.
  • Vertex broadened beyond CF with CASGEVY, JOURNAVX, and Crinetics, announced July 2026.
  • Vertex moves fast: CASGEVY pediatric FDA approval arrived 53 days after filing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Ticker Report
Aug 19th, 2026
Wealthfront Advisers LLC Makes New $20.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]

Yahoo Finance
Aug 14th, 2026
Vertex Pharmaceuticals hits all-time high despite CF competition risks

Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.

Yahoo Finance
Aug 12th, 2026
Vertex Pharmaceuticals beats Q2 revenue estimates with $3.33B, driven by CF portfolio and newer products

Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.

Yahoo Finance
Aug 11th, 2026
Vertex Q2 2026 revenue up 12% year-on-year, announces Crinetics acquisition

Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.

Yahoo Finance
Aug 7th, 2026
Sionna Therapeutics challenges Vertex Pharmaceuticals' $12B cystic fibrosis market dominance

Sionna Therapeutics is challenging Vertex Pharmaceuticals' dominance in the cystic fibrosis (CF) drug market. Vertex, valued at nearly $123 billion, generated $3.2 billion in CF-related sales in Q2, representing most of its $3.33 billion total revenue. Sionna, worth $2.2 billion, claims its approach could restore normal function to the CFTR protein, which causes CF when misfolded. Vertex's current treatments improve the protein's shape and function but don't restore normal function for most patients. Vertex generates over $12 billion annually from CF treatments. However, several companies, including AbbVie, have previously attempted to challenge Vertex's market position without success. Vertex has maintained its position since receiving its first CF drug approval in 2012.